BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $88 from $90 but keeps an Outperform rating on the shares. The company expects to disclose pivotal data evaluating vepdegestrant in ER+/HER2- breast cancer patients in Q1 of 2025, and the firm is maintaining its positive view on Arvinas’ protein degrader platform and ARV-471 in ER+/HER2- breast cancer, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.